In the latest development regarding Caring Patients Monkeypox, Caring for Patients with Monkeypox | Monkeypox | CDC

Key Takeaways & Highlights

  • Secure .gov websites use HTTPS A lock ( ) or https:// means you've safely connected to the .gov website.
  • Share sensitive information only on official, secure websites.Latest Developments and Impact Analysis Monkeypox Explore This Topic For Everyone Current Situation U.S.
  • Clinical Testing and Diagnosis Clinical Care Infection Control Guidance Veterinary Guidance View Menu Caring for Patients with Monkeypox Jan.

Key Background and Context

Skip directly to site content Skip directly to search

আরও পড়ুন
How many people in America skip medical treatment due to healthcare costs? - USAFacts

How many people in America skip medical treatment due to healthcare costs? - USAFacts

Nov 14, 2026

An official website of the United States government Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

ADVERTISEMENT
SPONSORED CONTENTCloudTech Solutions
How Next-Gen Cloud Infrastructure Is Supercharging Newsrooms Worldwide

Learn how top publishers optimize page speeds, reduce bounce rates, and increase ad revenue by up to 40%.

Read Full Story →
Sponsored Feature

Latest Developments and Impact Analysis

Monkeypox Explore This Topic

For Everyone Current Situation U.S. Case Data About Signs and Symptoms Outbreaks How It Spreads Prevention Vaccines View all Health Care Providers Clinical Overview Clinical Signs and Symptoms Vaccine for Monkeypox Prevention in the U.S. Clinical Testing and Diagnosis Clinical Care Infection Control Guidance Veterinary Guidance View all Public Health Case Definitions Community Monitoring & Risk Assessment Guidance for Health Departments Laboratory Information Communications Resources View all Home

search

Monkeypox Menu

For Everyone Current Situation U.S. Case Data About Signs and Symptoms Outbreaks How It Spreads Prevention Vaccines View All Home Health Care Providers Clinical Overview Clinical Signs and Symptoms Vaccine for Monkeypox Prevention in the U.S. Clinical Testing and Diagnosis Clinical Care Infection Control Guidance Veterinary Guidance View All Public Health Case Definitions Community Monitoring & Risk Assessment Guidance for Health Departments Laboratory Information Communications Resources View All Monkeypox

Clinical Overview Clinical Signs and Symptoms Vaccine for Monkeypox Prevention in the U.S. Clinical Testing and Diagnosis Clinical Care Infection Control Guidance Veterinary Guidance View Menu

Caring for Patients with Monkeypox

Jan. 15, 2026 Key points Regardless of clade, monkeypox can be spread, treated, and prevented the same way. Most monkeypox patients without severe immunocompromise will recover with supportive care and pain control only. CDC's interim clinical guidance may assist clinicians in managing patients who have or are at risk for severe manifestations of monkeypox. There are no FDA-approved treatments specifically for monkeypox, but there are FDA-regulated medications that may help.

Treatment options Overview Currently there is no Food and Drug Administration (FDA)-approved treatment specifically for monkeypox. For most patients with monkeypox who don't have severe disease or risk factors for severe disease (e.g., severe immunocompromise), supportive care and pain control will help them recover. However, some patients have experienced severe manifestations of monkeypox, including:

Ocular infections Neurologic complications Myopericarditis Complications associated with mucosal (oral, rectal, genital) lesions Complications from uncontrolled viral spread due to moderate or severe immunocompromise, particularly advanced HIV infection

Patients who are severely immunocompromised or have certain skin conditions, such as eczema, are at particular risk of uncontrolled viral spread, which can be life-threatening. CDC has interim clinical guidance to assist clinicians in managing patients with severe manifestations of monkeypox. Treatment for these patients involves FDA–regulated drugs and biologics that are primarily stockpiled by the U.S. government for smallpox preparedness.

Keep in mind "Severe disease": when a patient has conditions such as hemorrhagic disease; a large number of lesions such that they are confluent; necrotic lesions; severe lymphadenopathy that can be necrotizing or obstructing (such as in airways); involvement of multiple organ systems and associated comorbidities (i.e., pulmonary involvement with nodular lesions; sepsis; encephalitis; myocarditis; ocular or periorbital infections); or other conditions requiring hospitalization.

Pain Management and Supportive Care Information on pain management for monkeypox patients

Clinical Considerations for Monkeypox in Immunocompromised People Monkeypox clinical care information for people who are immunocompromised

Clinical Considerations for Monkeypox in Children and Adolescents in the U.S. Considerations for healthcare providers managing pediatric patients with monkeypox

Monkeypox Clinical Care and Treatment During Pregnancy Clinical considerations for monkeypox patients who are pregnant or breastfeeding

Interim Clinical Considerations for Management of Ocular Monkeypox Clinical recommendations for managing ocular monkeypox

ADVERTISEMENT
CAREER ACCELERATOR
Accelerate Your Digital Career

Join thousands of professionals learning modern AI, analytics & leadership.

Available therapeutics Tecovirimat (also known as TPOXX, ST-246) Tecovirimat is an antiviral that was made available for treatment of certain patients with monkeypox under the CDC-held Expanded Access-Investigational New Drug (EA-IND) protocol during the global outbreak of monkeypox that began in 2022.

The compassionate use of tecovirimat was based on the animal efficacy data that showed survival benefit over placebo in lethal animal models. While it may be reasonable to anticipate that tecovirimat may provide benefit in treating some people with monkeypox, it was unknown whether and how the efficacy observed in animals may translate to humans with active disease.

Randomized clinical trials were launched in 2022 to evaluate the efficacy and safety of tecovirimat in people with monkeypox. Tecovirimat study results from clinical trials Two clinical trials (PALM007 and STOMP) sponsored by the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) were conducted to evaluate the safety and efficacy of tecovirimat in people with monkeypox.

These studies showed that while tecovirimat was safe, the time to resolution of monkeypox lesions was not different among participants who were randomized to receive tecovirimat compared to those who received placebo. PALM007 trial (NCT05559099) was launched in October 2022 by NIAID and the Democratic Republic of the Congo (DRC)'s National Institute for Biomedical Research to examine the safety and efficacy of tecovirimat for clade I monkeypox treatment in adults and children.

The randomized, placebo-controlled study enrolled 597 people with laboratory-confirmed monkeypox at two sites in the DRC. Study participants were randomly assigned to receive tecovirimat or placebo and were admitted to a hospital for at least 14 days, where they were monitored closely for safety and resolution of monkeypox lesions.

All participants received supportive care including nutrition, hydration, and treatment for secondary infections. Initial analyses released in August 2024 indicated that tecovirimat did not reduce the duration of monkeypox lesions among children and adults with clade I monkeypox in DRC.

However, the study's 1.7% overall mortality was much lower than the monkeypox mortality of 3.6% or higher reported among cases looked at together across all of the DRC, showing that better outcomes among people with monkeypox can be achieved when they are hospitalized and provided high-quality supportive care.

The hospitalization ensured serial specimens could be collected (e.g. blood and lesion swabs) and the patients could be monitored closely for lesion resolution as well as be provided with adequate nutrition, fluids, pain relief, and treatment for secondary infections and other complications.

Initial analyses released in December 2024 indicated that tecovirimat did not reduce the time to resolution of monkeypox lesions or have an effect on pain among adults with mild to moderate clade II monkeypox and a low risk of developing severe disease. The participants in the random arm of the study were in the U.S. and other countries; they were non-pregnant and non-lactating adults with clade IIb monkeypox who did not have severe immunocompromise or severe monkeypox.

In both studies, tecovirimat was well-tolerated with no drug-related serious adverse events. The role of tecovirimat in treatment of monkeypox in patients with severe immunocompromise, including advanced HIV, has not been determined and requires additional clinical trials. Tecovirimat access for treatment in certain patients with monkeypox Tecovirimat from the Strategic National Stockpile (SNS) will remain available for treatment of monkeypox in patients who have or are at high risk for severe illness as defined in the CDC-held expanded access IND protocol.

Those at high risk include people who:

Are severely immunocompromised patients (e.g., those with HIV with CD4